Drugs / Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00347958 | Aug 2006 → Feb 2008 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus-diphtheria-acellular pertussis (Tdap) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00347958 ↗ |
| Modality | Vaccine | “Tetanus-diphtheria-acellular pertussis (Tdap) vaccine” NCT00347958 ↗ |
| Route | Intramuscular | “0.5mL, Intramuscular (IM)” NCT00347958 ↗ |